Special Interview with Prof. Guohong Han, Xi'an International Medical Center Hospital
On September 25, 2025, during the 2025 China-America Liver Cancer Symposium - East Meets West, the Hepatoma Research Editorial Office had the privilege of interviewing Prof. Guohong Han, Director of the Digestive Disease Hospital at Xi'an International Medical Center Hospital, and Chief Physician and Professor in the Department of Digestive Intervention.
In the interview, Prof. Han shared insights into the current clinical strategies and recent advances in managing hepatocellular carcinoma (HCC), emphasizing the integration of locoregional and systemic therapies. He discussed key clinical factors that influence therapeutic synergy, highlighted distinctive aspects of HCC management in China, and presented his team's latest research on portal hemodynamics. Prof. Han also underscored the critical role of international multicenter collaboration in promoting multidisciplinary and comprehensive care for HCC patients.
Interview Questions
Q1: In your keynote, you discussed "East Meets West in HCC Management: Synergizing Locoregional and Systemic Approaches for High Tumor Burden." From your perspective, what are the key factors for achieving effective synergy between locoregional and systemic therapies in patients with a high tumor burden?
Q2: You mentioned an "East-West dialogue" in HCC treatment. In what ways do you think Chinese clinical practices provide unique insights for the international liver cancer community?
Q3: Your recent studies focus on portal pressure gradient (PPG) measurement after TIPS and the interventional management of Budd-Chiari syndrome. How do you envision these findings informing and optimizing the future management of HCC patients with portal venous complications?
Q4: Your team has extensive experience combining interventional therapies with immunotherapy or targeted agents. Based on your real-world observations, what are the main characteristics of these combination strategies in terms of efficacy and safety?
Q5: Regarding international multicenter collaborations, which research directions do you consider most critical for achieving meaningful breakthroughs in combining interventional and systemic therapies for HCC?
About the Interviewee
Prof. Guohong Han, M.D., Ph.D., is Director of the Digestive Disease Hospital at Xi'an International Medical Center Hospital and Chief Physician and Professor in the Department of Digestive Intervention. He is a member of the Baveno VII Consensus Group and its Scientific Committee, a Council Member of the Asia-Pacific Primary Liver Cancer Expert Council (APPLE), and Chairman of the Committee of Integrated Chinese and Western Medicine for Liver Cancer under the Chinese Anti-Cancer Association.
Prof. Han's clinical and research expertise centers on the interventional management of hepatobiliary and pancreatic tumors, portal hypertension, and liver vascular diseases. Key areas of his work include transjugular intrahepatic portosystemic shunt (TIPS), portal pressure gradient (PPG) measurement, Budd-Chiari syndrome, and combined locoregional-systemic therapies for HCC, such as Yttrium-90 (Y-90) selective internal radiation therapy (SIRT) and immuno-interventional combinations.
Stay tuned to Hepatoma Research for more exclusive interviews with global leaders advancing liver cancer research and precision oncology.
Managing Editor: Victoria Lee
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Hepatoma Research
